Clinicians should maintain a high index of suspicion for EuDKA in patients on SGLT2 inhibitors, particularly when unexplained metabolic acidosis occurs, even with only modest hyperglycemia. This evidence concerns the gene SLC5A2 and Hyperglycemia.